A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Sponsor: Amgen
Protocol Number: IST-CAR-2014-100701
Start Date: 11/21/2014
Active, estimate end date – end of November 2020
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Sponsor: Amgen
Protocol Number: IST-CAR-2014-100701
Start Date: 11/21/2014
Active, estimate end date – end of November 2020